Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

medical horizon llc - ambroxol (ambroxol hydrochloride) - syrup - 15mg/5ml

India - English - Central Drugs Standard Control Organization

vasu ph. - tab - 10

India - English - Central Drugs Standard Control Organization

vasu ph. - syr - 200ml

Singapore - English - HSA (Health Sciences Authority)

song shan - liquid preparation

Bangladesh - English - DGDA (Directorate General of Drug Administration)

novatek pharmaceuticals ltd. - ambroxol - syrup - 15 mg/5 ml

Singapore - English - HSA (Health Sciences Authority)

huamao agencies sdn. bhd. - liquid preparations (internal use)

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

huamao agencies sdn. bhd. - rhizoma atractylodis macrocephalae; radix rehmanniae preparata; radix codonopsis pilosulae; poria cocos.; herba epimedii sagittatum; gecko linnaeus gakkonidae; radix glycyrrhiza uralensis -

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios ancalmo - mentol - mentol....7.00 g / alcanfor....7.00 g / lidocaÍna clorhidrato....0.50 g / eucaliptol....3.00 g / salicilato de metilo....7.00 g

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione tablets are indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. phytonadione tablets are contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients [ see description (11) ] . risk summary published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes [see data]. there are maternal and fetal risks associated with vitamin k deficiency during pregnancy [see clinical considerations]. animal reproduction studies have not been conducted with phytonadione. the estimated background risk for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defect

United States - English - NLM (National Library of Medicine)

avpak - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione tablets are indicated in the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. phytonadione tablets are indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - hypoprothrombinemia secondary to antibacterial therapy; - hypoprothrombinemia secondary to administration of salicylates; - hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin k will not be absorbed. hypersensitivity to any component of this medication.